Shopping Cart

Your shopping cart is currently empty

GAL-021

Name: GAL-021
Brand: TargetMol
SKU: T3557
Price: 31 USD
Availability: InStock
Rating: 5 (10 reviews)

😃Good

Catalog No. T3557Cas No. 1380341-99-0

Alias GAL 021

GAL-021 an intravenous BKCa-channel blocker.

GAL-021

😃Good

Purity: 99.66%

Catalog No. T3557Alias GAL 021Cas No. 1380341-99-0

GAL-021 an intravenous BKCa-channel blocker.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$31	In Stock	In Stock
5 mg	$68	In Stock	In Stock
10 mg	$105	In Stock	In Stock
25 mg	$197	In Stock	In Stock
50 mg	$297	In Stock	In Stock
100 mg	$459	In Stock	In Stock
500 mg	$987	-	In Stock
1 mL x 10 mM (in DMSO)	$77	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products. If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.

Questions

Batch Information

Select Batch

Purity:99.66%

Appearance:Solid

Color:White

Resource Download

COA LCMS HNMR

Product Introduction

Bioactivity

Description	GAL-021 an intravenous BKCa-channel blocker.
In vitro	Using inside-out patches in GH3 cells, GAL-021 concentration-dependently inhibits single-channel KCa1.1 activity. When evaluated against 12 different cardiac ion channels, inhibition is 35% or less at 30 μM. No significant kinase inhibition is observed at 10 μM. At 30 μM in the radioligand binding assays, interactions (defined as >50% radioligand displacement) are detected at adenosine A1 (65% I), A2A (79% I, IC50: 5 μM), and A3 (93% I; IC50: 1 μM) receptors, at 5-HT2B receptors (60% I; IC50: 30 μM).
In vivo	GAL-021 administered intravenously (i.v.) mitigates opiate-induced respiratory depression in both rats and nonhuman primates, preserving morphine's analgesic effects in rats. Furthermore, its capacity to stimulate ventilation in rats is diminished following carotid sinus nerve transection. This ventilatory stimulation by GAL-021 is also reduced in mice devoid of the pore-forming α-subunit of the KCa 1.1 channel.
Kinase Assay	GAL-021 is dissolved in DMSO, and final assay concentration of DMSO is 0.1% or less. The effects of GAL-021 (30 μM) on a panel of 55 receptors, transporters, and ion channels are evaluated using radioligand binding analyses. Potential kinase inhibition by GAL-021 (10 μM) is assessed using the Kinase HotSpot Screen where activity of 50 kinases is measured in the presence of adenosine triphosphate (10 μM)[1].
Synonyms	GAL 021

Chemical Properties

Molecular Weight	254.33
Formula	C₁₁H₂₂N₆O
Cas No.	1380341-99-0
Smiles	CCCNc1nc(NCCC)nc(n1)N(C)OC
Relative Density.	1.164 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 50 mg/mL (196.59 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.86 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	3.9319 mL	19.6595 mL	39.3190 mL	196.5950 mL
5 mM	0.7864 mL	3.9319 mL	7.8638 mL	39.3190 mL
10 mM	0.3932 mL	1.9659 mL	3.9319 mL	19.6595 mL
20 mM	0.1966 mL	0.9830 mL	1.9659 mL	9.8297 mL
50 mM	0.0786 mL	0.3932 mL	0.7864 mL	3.9319 mL
100 mM	0.0393 mL	0.1966 mL	0.3932 mL	1.9659 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc